| Z06813 | |
|
|
|
| ¥90,607.00 | |
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 50.30 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. |
| Synonyms | CT83; HLA class I; MHC class I; HLA-A; HLA-A*0101; MHC; MHC HLA-A alpha; NTDNNLAVY |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
